Kalvista Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|---|
Revenue | $59,925 | $40,863 | $40,863 | $1,426 |
Gross Profit | 55,949 | 37,773 | 37,418 | 836 |
EBITDA | -10,925 | -23,087 | -54,165 | |
EBIT | -11,511 | -23,442 | -54,417 | |
Net Income | -5,372 | -23,487 | -23,487 | -60,096 |
Net Change In Cash | 59,925 | 40,863 | 40,863 | 1,426 |
Free Cash Flow | 45,520 | -14,658 | -14,576 | -54,792 |
Cash | 229,342 | 213,768 | 229,342 | 124,304 |
Basic Shares | 50,536 | 51,237 | 50,900 | 53,497 |
Annual Financials
| Values in thousands | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 |
|---|---|---|---|---|
Revenue | $73,617 | $0 | $0 | $0 |
Gross Profit | 67,542 | -941 | -86,167 | -802 |
EBITDA | -170,385 | -173,326 | -134,280 | -94,368 |
EBIT | -171,838 | -174,267 | -135,096 | -95,086 |
Net Income | -164,286 | -183,444 | -126,644 | -92,907 |
Net Change In Cash | 73,617 | 0 | 0 | 0 |
Cost of Revenue | 24,270 | |||
Free Cash Flow | -83,328 | -153,341 | -89,674 | -76,457 |
Cash | 229,342 | 98,644 | 31,789 | 56,238 |
Basic Shares | 50,900 | 49,652 | 36,786 | 27,890 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-04-30 | -$0.43 |
2026-01-31 | $0.94 |
2025-10-31 | -$0.92 |
2025-07-31 | -$1.12 |